Hangzhou Tigermed Consulting Co., Ltd 5HZ1.F Stock
Hangzhou Tigermed Consulting Co., Ltd Price Chart
Hangzhou Tigermed Consulting Co., Ltd 5HZ1.F Financial and Trading Overview
Hangzhou Tigermed Consulting Co., Ltd stock price | 3.82 EUR |
Previous Close | 6.15 EUR |
Open | 6.05 EUR |
Bid | 5.85 EUR x N/A |
Ask | 6.35 EUR x N/A |
Day's Range | 6.05 - 6.05 EUR |
52 Week Range | 5.85 - 13.5 EUR |
Volume | 78 EUR |
Avg. Volume | 11 EUR |
Market Cap | 7.77B EUR |
Beta (5Y Monthly) | 0.831164 |
PE Ratio (TTM) | 20.166666 |
EPS (TTM) | 0.3 EUR |
Forward Dividend & Yield | 0.07 (1.23%) |
Ex-Dividend Date | May 25, 2023 |
1y Target Est | N/A |
5HZ1.F Valuation Measures
Enterprise Value | 3.42B EUR |
Trailing P/E | 20.166666 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1.0984417 |
Price/Book (mrq) | 0.26019266 |
Enterprise Value/Revenue | 0.484 |
Enterprise Value/EBITDA | 1.801 |
Trading Information
Hangzhou Tigermed Consulting Co., Ltd Stock Price History
Beta (5Y Monthly) | 0.831164 |
52-Week Change | -39.99% |
S&P500 52-Week Change | 20.43% |
52 Week High | 13.5 EUR |
52 Week Low | 5.85 EUR |
50-Day Moving Average | 7.62 EUR |
200-Day Moving Average | 8.96 EUR |
5HZ1.F Share Statistics
Avg. Volume (3 month) | 11 EUR |
Avg. Daily Volume (10-Days) | 65 EUR |
Shares Outstanding | 123.13M |
Float | 626.95M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 75.31% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0.55 |
Trailing Annual Dividend Yield | 8.94% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.2067 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 29.08% |
Operating Margin (ttm) | 24.47% |
Gross Margin | 39.84% |
EBITDA Margin | 26.87% |
Management Effectiveness
Return on Assets (ttm) | 4.08% |
Return on Equity (ttm) | 10.18% |
Income Statement
Revenue (ttm) | 7.07B EUR |
Revenue Per Share (ttm) | 8.18 EUR |
Quarterly Revenue Growth (yoy) | -0.70% |
Gross Profit (ttm) | 2.81B EUR |
EBITDA | 1.9B EUR |
Net Income Avi to Common (ttm) | 2.06B EUR |
Diluted EPS (ttm) | 0.3 |
Quarterly Earnings Growth (yoy) | 9.70% |
Balance Sheet
Total Cash (mrq) | 7.65B EUR |
Total Cash Per Share (mrq) | 8.83 EUR |
Total Debt (mrq) | 2.83B EUR |
Total Debt/Equity (mrq) | 12.14 EUR |
Current Ratio (mrq) | 2.954 |
Book Value Per Share (mrq) | 23.252 |
Cash Flow Statement
Operating Cash Flow (ttm) | 1.08B EUR |
Levered Free Cash Flow (ttm) | -398932448 EUR |
Profile of Hangzhou Tigermed Consulting Co., Ltd
Country | Germany |
State | N/A |
City | Hangzhou |
Address | F18, Building A – Shengda Science Park |
ZIP | 310051 |
Phone | 86 57 1288 87227 |
Website | https://www.tigermed.net |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 9233 |
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Q&A For Hangzhou Tigermed Consulting Co., Ltd Stock
What is a current 5HZ1.F stock price?
Hangzhou Tigermed Consulting Co., Ltd 5HZ1.F stock price today per share is 3.82 EUR.
How to purchase Hangzhou Tigermed Consulting Co., Ltd stock?
You can buy 5HZ1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Hangzhou Tigermed Consulting Co., Ltd?
The stock symbol or ticker of Hangzhou Tigermed Consulting Co., Ltd is 5HZ1.F.
Which industry does the Hangzhou Tigermed Consulting Co., Ltd company belong to?
The Hangzhou Tigermed Consulting Co., Ltd industry is Diagnostics & Research.
How many shares does Hangzhou Tigermed Consulting Co., Ltd have in circulation?
The max supply of Hangzhou Tigermed Consulting Co., Ltd shares is 1.53B.
What is Hangzhou Tigermed Consulting Co., Ltd Price to Earnings Ratio (PE Ratio)?
Hangzhou Tigermed Consulting Co., Ltd PE Ratio is 12.73333300 now.
What was Hangzhou Tigermed Consulting Co., Ltd earnings per share over the trailing 12 months (TTM)?
Hangzhou Tigermed Consulting Co., Ltd EPS is 0.3 EUR over the trailing 12 months.
Which sector does the Hangzhou Tigermed Consulting Co., Ltd company belong to?
The Hangzhou Tigermed Consulting Co., Ltd sector is Healthcare.